AbSci (ABSI)
NASDAQ:ABSI
ABSI Stock Chart & Stats
$3.01
$0.12(3.91%)
At close: 4:00 PM EST
$3.01
$0.12(3.91%)
Day’s Range― - ―
52-Week Range$2.01 - $5.23
Previous CloseN/A
Volume51.94M
Average Volume (3M)3.28M
Market Cap
$440.59M
Enterprise Value$449.36M
Total Cash (Recent Filing)$152.47M
Total Debt (Recent Filing)$6.22M
Price to Earnings (P/E)―
Beta2.15
Next Earnings
May 19, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding150,371,540
10 Day Avg. Volume4,536,912
30 Day Avg. Volume3,280,260
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)2.52
Price to Sales (P/S)0.00
P/FCF Ratio-5.08
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue159.63
Enterprise Value/Gross Profit-8.81
Enterprise Value/Ebitda-4.32
Forecast
1Y Price Target
$7.64Price Target Upside153.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.68
Revenue Forecast (FY)$18.42M
Bulls Say, Bears Say
Bulls Say
Clinical TolerabilityEarly dosing cohorts showed the drug to be well tolerated, lowering safety-related development risk and supporting continued progression through planned study stages.
Patient Preference And Commercial PotentialSurvey data indicate many women concerned about hair loss are willing to try new therapies and show a clear preference for an infrequent injectable, which could translate into stronger commercial uptake versus daily topicals.
Proof-of-concept And Program ExpansionThe multiple-dose portion of the study is designed to be sufficiently powered to demonstrate proof of concept and could enable expansion of the program into an endometriosis indication if results are supportive.
Bears Say
Existing Treatment SatisfactionA substantial portion of surveyed patients reported satisfaction with current treatments, which could reduce uptake of a new therapy despite potential advantages.
Limited Early Efficacy InsightSingle-dose data will focus on safety, tolerability and drug behavior in the body rather than providing an early efficacy readout, leaving clinical benefit unproven until multiple-dose results are available.
Regulatory And Macro UncertaintyAnalyst warns that regulatory unpredictability and broader macroeconomic uncertainty could weigh on biotech valuations and slow deal activity for the program.
AbSci News
ABSI FAQ
What was AbSci’s price range in the past 12 months?
AbSci lowest stock price was $2.01 and its highest was $5.23 in the past 12 months.
What is AbSci’s market cap?
AbSci’s market cap is $440.59M.
When is AbSci’s upcoming earnings report date?
AbSci’s upcoming earnings report date is May 19, 2026 which is in 55 days.
How were AbSci’s earnings last quarter?
AbSci released its earnings results on Mar 24, 2026. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of -$0.178 by -$0.022.
Is AbSci overvalued?
According to Wall Street analysts AbSci’s price is currently Undervalued.
Does AbSci pay dividends?
AbSci does not currently pay dividends.
What is AbSci’s EPS estimate?
AbSci’s EPS estimate is -0.19.
How many shares outstanding does AbSci have?
AbSci has 150,371,540 shares outstanding.
What happened to AbSci’s price movement after its last earnings report?
AbSci reported an EPS of -$0.2 in its last earnings report, missing expectations of -$0.178. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of AbSci?
Currently, no hedge funds are holding shares in ABSI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AbSci Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.64 (153.82% Upside)
$7.64 (153.82% Upside)
Blogger Sentiment
Bullish
ABSI Sentiment 66%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $96.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-2.90%
12-Months-Change
Fundamentals
Return on Equity
-60.49%
Trailing 12-Months
Asset Growth
4.15%
Trailing 12-Months
Company Description
AbSci
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
ABSI Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Absci Corporation's strategic focus on expanding its pipeline and leveraging its AI platform for drug discovery. Significant progress was made in the development of ABS-201, with promising market opportunities in AGA and endometriosis. Despite challenges with ABS-101, the company remains financially robust and anticipates new partnerships, indicating a positive outlook.View all ABSI earnings summariesABSI Stock 12 Month Forecast
Average Price Target
$7.64
▲(153.82% Upside)
Technical Analysis
Autolus Therapeutics
―
―
ADC Therapeutics
―
4D Molecular Therapeutics
―
Design Therapeutics
―
Ownership Overview
6.81% Insiders
20.72% Mutual Funds
27.57% Other Institutional Investors
24.81% Public Companies and
Individual Investors